Hepatitis C and treatment with pegylated interferon and ribavirin

Int J Biochem Cell Biol. 2004 Oct;36(10):1874-7. doi: 10.1016/j.biocel.2004.03.014.

Abstract

Hepatitis C is a hepatotropic RNA virus with a propensity to cause chronic infection, causing a worldwide burden of chronic hepatitis, cirrhosis and hepatocellular carcinoma. Both viral elimination and hepatocellular damage are thought to be immune mediated with T-helper and cytotoxic T-lymphocytes central to these events. A delay in the onset of adaptive immunity following infection indicates that a defect in the innate immune response may lead to viral persistence with a combination of other mechanisms subsequently contributing. Antiviral therapy based on interferon-alpha leads to resolution of disease in approximately 50% of patients. Specific anti-hepatitis C anti-viral drugs are being developed.

Publication types

  • Review

MeSH terms

  • Hepacivirus / genetics
  • Hepacivirus / physiology
  • Hepatitis C / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Polyethylene Glycols / therapeutic use*
  • Recombinant Proteins
  • Ribavirin / therapeutic use*
  • Virus Replication / physiology

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a